Document is current
Any future updates will be listed below
-
Authors
Wigerinck, Stijn
Schellekens, Pieter
Smith, Byron H.
Hanna, Christian
Dachy, Angelique
Chedid, Maroun
Borghol, Abdul Hamid
Senum, Sarah R.
Bockenhauer, Detlef
Harris, Peter C.
Jouret, Francois
Bammens, Bert
Chebib, Fouad T.
Mekahli, Djalila https://orcid.org/0000-0003-0954-6088
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0C8920N, G060623N, 1804123N)
Otsuka America Pharmaceutical
Vertex Pharmaceuticals
Natera
- License Information
-
More Information
Article History
Received: 9 July 2024
Revised: 20 November 2024
Accepted: 12 December 2024
First Online: 1 February 2025
Declarations
:
: D.M. is supported by the Research Foundation Flanders (FWO) under the grants G0C8920N, G060623N, and the clinical senior research grant 1804123N. D.M., B.B., and D.B. are ERKNet members. P.C.H. reports a position on the Clinical Advisory Board of Mironid, honoraria from Otsuka Pharmaceuticals and Vertex Pharmaceuticals, and other fees from Otsuka Pharmaceuticals. F.T.C. receives research funding from Natera Inc. and Otsuka Pharmaceuticals. He is Chair of the educational advisory panel at the PKD foundation in the USA. All other authors declared no conflict of interest.
